Patent Issued for Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors (USPTO 12157891).

Regeneron Pharmaceuticals Inc. has been issued a patent for the treatment of uveitis using endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors. Uveitis is an inflammation of the middle layer of the eye and can lead to severe vision impairment. The patent outlines methods for treating uveitis by administering ERAP1 inhibitors and identifying individuals at increased risk of developing the condition based on genetic markers. This research has implications for the development of therapies for eye diseases and conditions. [Extracted from the article]